TCR2 Therapeutics Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics or view top-rated stocks.

Wall Street analysts have given TCR2 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TCR2 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

TCR2 Therapeutics saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 3,080,000 shares, a decline of 13.5% from the May 13th total of 3,560,000 shares. Based on an average daily volume of 477,900 shares, the days-to-cover ratio is presently 6.4 days. Approximately 9.6% of the shares of the company are sold short.
View TCR2 Therapeutics' Short Interest.

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for TCR2 Therapeutics.

TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its quarterly earnings data on Thursday, May, 13th. The company reported ($0.58) EPS for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.05.
View TCR2 Therapeutics' earnings history.

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCRR stock has increased by 103.4% and is now trading at $17.45.
View which stocks have been most impacted by COVID-19.

8 brokers have issued 1 year price objectives for TCR2 Therapeutics' shares. Their forecasts range from $34.00 to $56.00. On average, they anticipate TCR2 Therapeutics' stock price to reach $45.14 in the next twelve months. This suggests a possible upside of 158.7% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to TCR2 Therapeutics include Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Revolution Medicines (RVMD), Instil Bio (TIL), Rubius Therapeutics (RUBY), bluebird bio (BLUE), Kymera Therapeutics (KYMR), Alector (ALEC), Cortexyme (CRTX), C4 Therapeutics (CCCC), Sangamo Therapeutics (SGMO), Replimune Group (REPL), REGENXBIO (RGNX), Immunocore (IMCR) and Translate Bio (TBIO).
View all of TCRR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

TCR2 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Redmile Group LLC (9.47%), BlackRock Inc. (8.04%), Victory Capital Management Inc. (3.23%), Cormorant Asset Management LP (2.36%), First Light Asset Management LLC (2.17%) and JPMorgan Chase & Co. (1.72%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics.

TCRR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Hillhouse Capital Advisors LTD., Verition Fund Management LLC, Rothschild & Co. Asset Management US Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, Sei Investments Co., and Granite Point Capital Management L.P.. Company insiders that have sold TCR2 Therapeutics company stock in the last year include Mayur Ian Somaiya, and Robert Hofmeister.
View insider buying and selling activity for TCR2 Therapeutics or view top insider-selling stocks.

TCRR stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., First Light Asset Management LLC, Redmile Group LLC, BlackRock Inc., Cormorant Asset Management LP, Dimensional Fund Advisors LP, Tekla Capital Management LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for TCR2 Therapeutics or or view top insider-buying stocks.

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TCRR stock can currently be purchased for approximately $17.45.

TCR2 Therapeutics has a market capitalization of $665.93 million. The company earns $-67,120,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

TCR2 Therapeutics employs 118 workers across the globe.

The official website for TCR2 Therapeutics is www.tcr2.com.

TCR2 Therapeutics is headquartered at 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142.

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]